Health News Roundup: Major Settlements, Funding Boosts, and Technological Advances

This summary highlights key developments in the health sector, including Johnson & Johnson's $6.5-billion talc settlement, Biden's $150 million 'Cancer Moonshot' funding, Carlyle's $3.8 billion acquisition of Vantive, Africa CDC's mpox emergency, and more. Significant advancements in vaccines, gene sequencing, and drug disputes are also discussed.

A series of significant developments in the health sector were reported today. Johnson & Johnson has garnered enough claimant support for a $6.5-billion talc lawsuit settlement, clearing a critical hurdle for its third bankruptcy bid, according to Bloomberg.

In other news, President Joe Biden announced a $150 million boost to the 'Cancer Moonshot' program, aimed at advancing technology for the removal of cancerous tumors. This is part of a broader initiative to halve the U.S. cancer death rate by 2047.

Meanwhile, Carlyle Group will acquire Baxter's kidney-care unit Vantive for $3.8 billion. The funds will help Baxter reduce its substantial debt.

Africa's CDC has declared a public health emergency over an escalating mpox outbreak. Additionally, Enzo Biochem will pay $4.5 million to settle regulatory charges stemming from a cyberattack that compromised patient data. Regulatory and legal battles continue as Novartis fails to block a generic version of its heart-failure drug, and Pfizer reports promising results for its RSV vaccine in immuno-compromised adults. The USDA and France are also responding to bird flu outbreaks with expanded testing and precautions.